{"title":"萘普生对宫内节育器致痛经的影响。","authors":"N Pedron, R Aznar","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>48 volunteers using either a Lippes Loop D or a T Cu 220C IUD who subjectively observed an increase in menstrual bleeding associated with IUD use received 250 mg naproxen 3 times/day during, or for 5 days of, their menstrual period. Results were compared with those on administration of placebo. Of the 48 women studied, 14 had hypermenorrhea (average 133.4 ml/menstrual cycle; heavy bleeding group) and 34 had blood loss within the normal range (average 47 ml; normal group). The study consisted of measuring menstrual blood loss (MBL) during the 1st (control cycle). During the 2nd cycle, the women received placebo medication 3 times/day for the 5 days of menses; results were not significantly different from control values. Naproxen was administered during the 3rd and 4th cycles (treatment); a significant reduction in the amount of MBL was observed in the group of women with heavy bleeding. During the 1st treatment cycle, a reduction of 42.8% was observed and during the 2nd treatment cycle, the reduction was 24.2%. In the group of women with MBL within the range of normal, no significant change in the amount of menstrual bleeding was observed in the treatment cycles as compared with the control cycle or placebo administration.</p>","PeriodicalId":84493,"journal":{"name":"Contraceptive delivery systems","volume":"4 1","pages":"39-42"},"PeriodicalIF":0.0000,"publicationDate":"1983-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of naproxen on IUD-induced hypermenorrhea.\",\"authors\":\"N Pedron, R Aznar\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>48 volunteers using either a Lippes Loop D or a T Cu 220C IUD who subjectively observed an increase in menstrual bleeding associated with IUD use received 250 mg naproxen 3 times/day during, or for 5 days of, their menstrual period. Results were compared with those on administration of placebo. Of the 48 women studied, 14 had hypermenorrhea (average 133.4 ml/menstrual cycle; heavy bleeding group) and 34 had blood loss within the normal range (average 47 ml; normal group). The study consisted of measuring menstrual blood loss (MBL) during the 1st (control cycle). During the 2nd cycle, the women received placebo medication 3 times/day for the 5 days of menses; results were not significantly different from control values. Naproxen was administered during the 3rd and 4th cycles (treatment); a significant reduction in the amount of MBL was observed in the group of women with heavy bleeding. During the 1st treatment cycle, a reduction of 42.8% was observed and during the 2nd treatment cycle, the reduction was 24.2%. In the group of women with MBL within the range of normal, no significant change in the amount of menstrual bleeding was observed in the treatment cycles as compared with the control cycle or placebo administration.</p>\",\"PeriodicalId\":84493,\"journal\":{\"name\":\"Contraceptive delivery systems\",\"volume\":\"4 1\",\"pages\":\"39-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1983-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Contraceptive delivery systems\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contraceptive delivery systems","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
48名使用Lippes Loop D或T Cu 220C宫内节育器的志愿者主观观察到与使用宫内节育器相关的月经出血增加,他们在月经期间或5天内接受250毫克萘普生,每天3次。结果与安慰剂组进行比较。在研究的48名女性中,14名有痛经(平均133.4毫升/月经周期;大出血组34例,出血量在正常范围内(平均47 ml;正常组)。本研究包括在第一个(对照周期)测量月经失血量(MBL)。在第二个周期中,女性在5天的月经周期中接受安慰剂治疗3次/天;结果与对照组无显著差异。在第3和第4周期(治疗)给予萘普生;在大量出血的妇女组中观察到MBL的数量显著减少。在第一个治疗周期,观察到减少42.8%,在第二个治疗周期,减少24.2%。在正常范围内的MBL妇女组中,与对照组或安慰剂组相比,在治疗周期中未观察到月经出血量的显著变化。
48 volunteers using either a Lippes Loop D or a T Cu 220C IUD who subjectively observed an increase in menstrual bleeding associated with IUD use received 250 mg naproxen 3 times/day during, or for 5 days of, their menstrual period. Results were compared with those on administration of placebo. Of the 48 women studied, 14 had hypermenorrhea (average 133.4 ml/menstrual cycle; heavy bleeding group) and 34 had blood loss within the normal range (average 47 ml; normal group). The study consisted of measuring menstrual blood loss (MBL) during the 1st (control cycle). During the 2nd cycle, the women received placebo medication 3 times/day for the 5 days of menses; results were not significantly different from control values. Naproxen was administered during the 3rd and 4th cycles (treatment); a significant reduction in the amount of MBL was observed in the group of women with heavy bleeding. During the 1st treatment cycle, a reduction of 42.8% was observed and during the 2nd treatment cycle, the reduction was 24.2%. In the group of women with MBL within the range of normal, no significant change in the amount of menstrual bleeding was observed in the treatment cycles as compared with the control cycle or placebo administration.